Clinical Senior Lecturer in Medical Oncology

London (Central), London (Greater)
£76,761 - £103,490 p.a
26 Oct 2018
23 Nov 2018
Oncology, Other
Career Level
Contract Type
Fixed Contract
Full Time

Department/Division/Faculty: Department of Surgery & Cancer, Division of Cancer, Faculty of Medicine

Salary: £76,761 - £103,490 p.a. dependent on level of seniority, plus £2,162 London Weighting Allowance per annum

Campus: Hammersmith Hospital Campus – may be required to travel to Charing Cross Hospital Campus

Increased early phase trials activity in solid tumour oncology has been identified as a strategic priority in Division of Cancer and Department of Surgery and Cancer.

Success of the CRUK Centre, ECMC and BRC renewals is predicated upon increasing the portfolio of early phase trials in cancer – particularly as a conduit for clinical translation of scientific discoveries within the Centre but also to ensure that we establish a broad portfolio of clinical trials ranging from phase I to phase III to offer patients. There is also a developing pipeline of new anti-cancer drugs emerging from Imperial, exemplified by the first-in-class CDK7 inhibitor ICEC-0942 (CT7001), and it is imperative that we are able to take these studies into phase I trial at Imperial.

The successful candidate will play a critical role in achieving Departmental and Divisional goals for early clinical trials expansion – and of meeting goals set out in ECMC, CRUK centre and BRC cancer theme renewals. 

The post holder is expected to act as Principal and Chief Investigator in early phase (especially phase IB and IIA) clinical trials across solid tumour oncology as well as have a disease-specific interest.  There is no mandated tumour-specific interest, but alignments with the Division’s main cancer areas (prostate, breast, gynaecological and hepatopancreatobiliary malignancies) is strongly preferred. Close working with the NIHR/Wellcome Trust Clinical Research Facility (Director Professor Martin Wilkins) will be essential for early phase trial delivery.

This role will also facilitate the clinical translation of preclinical research.  The post holder will co-supervise PhD students and clinical research fellows with non-clinical researchers.  In addition, the post holder will have a disease-specific interest (preferably in prostate, breast, gynaecological and hepatopancreatobiliary malignancies), and thus should link specifically with the research teams working within those cancer fields.

The post holder will develop partnerships with the pharmaceutical industry, to bring novel agents and novel clinical trials to Imperial College  and enhance its reputation and build a critical mass of early phase studies.
The post holder is expected to generate research income from clinical trials – largely industry-sponsored, but also funded from clinical trials grants from Cancer Research UK, MRC, NIHR and other academic grant-funders.

Applicants must demonstrate how they meet the essential criteria required of the post but in particular, must have GMC registration, appropriate specialist qualification, a national and developing international reputation in their field of research, experience and capabilities to act as a role model in areas of research, teaching and management and excellent leadership skills. In addition, applicants are expected to have attained experience of teaching undergraduate and postgraduate students, be able to communicate effectively and have extensive experience in medical oncology.

This post is full time and fixed term for 5 years in the first instance.

Further information about the Department of Surgery & Cancer can be located here:

Reference number: MED00829

Closing date: 23 November 2018

To apply, please click the apply button.

Imperial Expectations guide the behaviour of all our staff.

Should you have any queries please contact:

Professor Iain McNeish -

Committed to equality and valuing diversity, we are also an Athena SWAN Silver Award winner, a Stonewall Diversity Champion, a Disability Confident Employer and are working in partnership with GIRES to promote respect for trans people.

The College is a proud signatory to the San-Francisco Declaration on Research Assessment (DORA), which means that in hiring and promotion decisions, we evaluate applicants on the quality of their work, not the journal impact factor where it is published. For more information, see